PREVIOUS
✖
Nuvaxovid COVID vaccine
June 5 , 2025
3 days
67
0
- Novavax (Nuvaxovid) has secured a full FDA of USA approval for its protein-based COVID-19 vaccine.
- Nuvaxovid (NVX-CoV2705) is an updated version of Novavax's prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the JN.1 variant.
- It is a protein-based vaccine (Not mRNA) made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19.
- The non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus.
Leave a Reply
Your Comment is awaiting moderation.